Treatment of Capecitabine Corneal Side Effects With Autologous Blood-derived Serum Eye Drops

Abstract

Background/Aim: To describe the clinical progress and management of ocular side effects in a 35-yearold patient with metastatic breast cancer who underwent oral chemotherapy with capecitabine and lapatinib. Materials and Methods: Slit lamp evaluation revealed bilateral perikeratic hyperemia, perilimbal conjunctival edema associated with corneal marginal infiltrates and epithelial and anterior stromal defects in both eyes. Slit lamp examination, in vivo confocal microscopy and anteriorsegment optical coherence tomography were highly suggestive for limbal stem cell deficiency. The decision to administer autologous blood-derived serum eye drops was made. Results: Following administration of autologous blood-derived serum eye drops, corneal marginal infiltrates, epithelial and stromal defects significantly regressed in both eyes after only 10 days. Chemotherapy was resumed and serum eye drops were prescribed simultaneously. Conclusion: Autologous blood-derived serum eye drops may be an adequate therapeutic choice for bilateral corneal lesions detected as ocular side effects of capecitabine. Capecitabine (C), a fluoropyrimidine carbamate, is an antimetabolite agent indicated for the treatment of breast cancer refractory to paclitaxel or anthracycline. Xeloda (C,

Autologous Serum Eye Drops in the Management of Limbal Stem Cell Deficiency Associated With Glaucoma Surgery

“…19,20 Reversibility of severe contact lens- induced LSCD and improvement of BCVA with the 2-month use of 20% AS treatment was reported by Yeh et al 14 A recent report by Di Staso F et al showed that 30% AS could reverse corneal toxicity resembling LSCD from capecitabine. 21 It is unclear whether the mechanism with which chronic contact lens use leads to LSCD is similar to that of LSCD in glaucoma surgery patients. This underlines the need to further assess how potentially alternative routes of acquiring LSCD affect the efficacy of AS treatment.…”